URGN’s Urogen gains options for exclusive worldwide Oncology license
URGN’s intragel Therapeutics unit, Urogen, gains options for an exclusive worldwide license to develop up to three Oncology products, according to Hammerstone MarketTalk.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.